Know Your Ports - Oncology Nursing News
Dec 21, 2017 · Throughout the course of treatment, many patients with cancer receive chemotherapy, intravenous fluids, antibiotics, and much more via central venous catheters …
T-DXd Improves PFS in HR+, HER2-Low/-Ultralow Metastatic …
Dec 11, 2024 · Treatment with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) demonstrated an improvement in progression-free survival (PFS), compared with treatment of physician’s …
Evaluating Targeted Therapies: MARIPOSA Trial Aids APPs in …
Jan 3, 2025 · As the treatment landscape continues to evolve in non-small cell lung cancer (NSCLC), understanding options for those with advanced, treatment-naïve EGFR-positive …
Tislelizumab Plus Chemotherapy Receives FDA Approval for First …
Dec 27, 2024 · The FDA has approved tislelizumab-jsgr (Tevimbra) for use with platinum- and fluoropyrimidine-based chemotherapy in the first-line setting for unresectable or metastatic, …
Adjuvant Olaparib Continues to Improve iDFS in BRCA1/2+, HER2
Dec 12, 2024 · The analysis occurred at a median follow-up of 6.1 years (max, 9.6 years) and 2.6 years since the previous analysis. The updated data for all first invasive disease-free survival …
How ctDNA Testing Is Being Used To Diagnose And Monitor Cancer
Dec 18, 2024 · “ctDNA testing looks for small pieces of DNA found in a patient’s blood that comes from cancer cells and tumors,” Grafton explains. “Screening for ctDNA can be used to detect …
FDA Approves Durvalumab in Limited-Stage Small Cell Lung Cancer
Dec 5, 2024 · Results from the phase 3 ADRIATIC trial (NCT03703297) led to the approval. 2 A total of 730 patients were enrolled and randomly assigned 1:1:1 to either durvalumab …
MR-Linac Reduced Radiation to Healthy Brain Tissue in Glioma
Oct 12, 2024 · Adding weekly online MR-Linac (MRL) adaptive radiotherapy to temozolomide (Temodar) reduced clinical target volume (CTV) margins and limited exposure to normal brain …
Perioperative Pembrolizumab Combo Yields Durable Survival in …
Jan 2, 2025 · Long-term follow-up showed that neoadjuvant pembrolizumab (Keytruda) and chemotherapy followed by surgery and adjuvant pembrolizumab continued to improve event …
FDA Approves First and Only Systemic Therapy for NRG1+ Lung, …
Dec 4, 2024 · The FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri) as the first systemic therapy for patients with non-small cell lung cancer (NSCLC) or pancreatic …